Mitochondria are targets for the antituberculosis drug rifampicin in cultured epithelial cells

被引:0
作者
M. V. Erokhina
A. V. Kurynina
G. E. Onishchenko
机构
[1] Lomonosov Moscow State University,Faculty of Biology
[2] Russian Academy of Medical Sciences,Central Tuberculosis Research Institute
来源
Biochemistry (Moscow) | 2013年 / 78卷
关键词
rifampicin; fragmentation and pathology of mitochondria; oxidative stress; apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
Rifampicin is a widely used drug for antituberculosis therapy. Its target is the bacterial RNA polymerase. After entry into the human or mammalian organism, rifampicin is accumulated in cells of epithelial origin (kidneys, liver, lungs) where it induces apoptosis, necrosis, and fibrosis. The purpose of this study was to determine the intracellular mechanisms leading to rifampicin-induced pathological changes and cell death. We analyzed the survival and state of the chondriome of cultured epithelial cells of the SPEV line under the influence of rifampicin. Our data show that the drug induces pronounced pathological changes in the network and ultrastructure of mitochondria, and their dysfunction results in excessive production of reactive oxygen species and release of cytochrome c. These data suggest the initiation of the mitochondrial pathway of apoptosis. Simultaneously, we observed inhibition of cell proliferation and changes in morphology of the epithelial cells toward fibroblast-like appearance, which could indicate induction of epithelial-mesenchymal transition. Thus, mitochondria are the main potential target for rifampicin in cells of epithelial origin. We suggest that similar mechanisms of pathological changes can be induced in vivo in organs and tissues accumulating rifampicin during chemotherapy of bacterial infectious diseases.
引用
收藏
页码:1155 / 1163
页数:8
相关论文
共 205 条
  • [1] Bottcher T(2000)undefined J. Infect. Dis. 181 2095-2098
  • [2] Gerber J(2009)undefined Tuberkulez i Bolezni Legkikh 11 49-55
  • [3] Wellmer A(2010)undefined Antibiotiki i Khimioterapiya 55 25-29
  • [4] Smirnov A(2009)undefined BMC Cancer 9 3-141
  • [5] Fakhrjanali F(2013)undefined Neurol. Sci. 34 137-844
  • [6] Mix E(1967)undefined Biochim. Biophys. Acta 145 843-912
  • [7] Pilz J(2001)undefined Cell 104 901-1481
  • [8] Zettl U K(1999)undefined Science 283 1476-56
  • [9] Nau R(1970)undefined FEBS Lett. 10 54-2145
  • [10] Erokhina M B(1978)undefined Biochem. Pharmacol. 27 2139-3297